ArticlePloS one2025
Effect of calcium dobesilate on macular microvasculature in patients with diabetic retinopathy.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the impact of calcium dobesilate (CaD) on the macular microvasculature in patients with diabetic retinopathy (DR) using optical coherence tomography angiography.
methodsIn this retrospective study, patients with DR were divided into two groups: those treated with 1 g/day of CaD (Group 1) and those without CaD treatment (Group 2). Following the baseline, patients underwent two additional examinations at 3-month intervals for analysis. The vessel density of the superficial vascular complex (SVD) and deep vascular complex (DVD) were compared against prior assessments. Generalized linear mixed models analyzed factors associated with changes in SVD and DVD over time.
resultsA total of 81 eyes were included: 39 in Group 1 and 42 in Group 2. The mean SVD was 21.8 ± 5.7% at baseline, 23.5 ± 6.5% at 3 months, and 23.3 ± 6.1% at 6 months in Group 1, respectively (P = 0.034), with significant changes observed from baseline to 3 months (P = 0.021), but not from 3 to 6 months (P = 0.745). The mean DVD was 18.2 ± 3.4% at baseline, 20.0 ± 3.9% at 3 months, and 19.9 ± 4.1% at 6 months in Group 1, respectively (P = 0.008), showing a significant increase from baseline to 3 months (P = 0.007), but not from 3 to 6 months (P = 0.825). Group 2 showed no significant changes over time in either SVD (P = 0.175) or DVD (P = 0.156). In Group 1, multivariate analysis identified DR severity as significantly associated with changes in SVD (estimate = 5.07, P = 0.016).
conclusionsThe administration of CaD positively influences macular microcirculation in DR patients, demonstrating its effectiveness even in advanced stages of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.